This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617. The limited data available suggest partial response rates of up to 70%–80% that was limited to as few as several weeks in some of the patients. Encouragingly, only stage 1 -2 hematologic toxicities and sporadically mild xerostomia and fatigue were reported as side effects.